Calliditas lead project in the clinical pipeline besides Nefecon/TARPEYO is Setanaxib targeting primary biliary cholangitis (PBC) in a pivotal phase 2b/3 study TRANSFORM. This study is now live after having randomized the first patient, and we can expect an interim read-out in H1 2023 that will further validate the potential and decide which dose will progress into phase 3.